丹麦子痫前期筛查(PRESIDE):全国验证研究
这项前瞻性研究在丹麦六所大学医院纳入8783名单胎孕妇,盲法计算FMF早孕期子痫前期筛查算法的检出率,并与丹麦现行基于母体危险因素的筛查策略比较。在10%假阳性率下,FMF算法对<34周分娩子痫前期的检出率为77.4%,对<37周为66.8%,对任何孕周为44.1%;现行策略在3.4%假阳性率下对<34周和<37周的检出率分别为25.0%和19.6%。作者认为该算法在丹麦人群中的表现与其他人群相符。
要点
- FMF算法在10%假阳性率下对<34周分娩子痫前期检出率为77.4%。
- FMF算法在10%假阳性率下对<37周分娩子痫前期检出率为66.8%。
- 现行丹麦策略在3.4%假阳性率下对<34周和<37周检出率分别为25.0%和19.6%。
核心结论
- 在这项丹麦大型多中心研究中,基于母体特征、MAP、UtA-PI、PlGF和PAPP-A的FMF算法在10%假阳性率下预测了77.4%的<34周分娩子痫前期和66.8%的<37周分娩子痫前期,提示该算法在丹麦队列中的表现与其他人群相符。
研究设计与样本
- 前瞻性研究,纳入2019年5月至2020年12月在六所丹麦大学医院接受早孕期超声筛查的8783名单胎孕妇,中位年龄30.8岁(IQR 28.1-33.9)。
- 收集母体特征、病史、MAP、UtA-PI、血清PAPP-A和PlGF,不进行子痫前期风险评估,记录阿司匹林使用情况,分娩后记录妊娠结局。
- 对8156名(92.9%)有完整风险评估数据的孕妇,盲法使用经丹麦人群调整的FMF筛查算法计算子痫前期检出率。
主要发现
- 8156名孕妇中303名(3.7%)发生子痫前期,其中55名(0.7%)为<37周分娩的子痫前期,16名(0.2%)为<34周分娩的子痫前期。
- 在10%假阳性率下,基于母体特征、MAP、UtA-PI、PlGF和PAPP-A的FMF联合筛查对<34周分娩子痫前期的检出率为77.4%(95% CI 57.6-97.2%),对<37周为66.8%(95% CI 54.4-79.1%),对任何孕周为44.1%(95% CI 38.5-49.7%)。
- 现行丹麦基于母体危险因素的筛查策略在3.4%假阳性率下对<34周和<37周分娩子痫前期的检出率分别为25.0%和19.6%。
- 在固定3.4%假阳性率下,包含母体特征、MAP、UtA-PI和PlGF的FMF算法对<34周和<37周分娩子痫前期的检出率分别为60.5%(95% CI 36.9-84.1%)和45.2%(95% CI 32.0-58.5%)。
临床怎么用
- 作者认为该算法在丹麦队列中的表现与其他人群相符,原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the predictive performance of the Fetal Medicine Foundation (FMF) first-trimester screening algorithm for pre-eclampsia in a Danish population and compare screening performance with that of the current Danish strategy, which is based on maternal risk factors. METHODS: This was a prospective study of women with a singleton pregnancy attending for their first-trimester ultrasound scan and screening for aneuploidies at six Danish university hospitals between May 2019 and December 2020. Prenatal data on maternal characteristics and medical history were recorded, and measurements of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum pregnancy-associated plasma protein-A (PAPP-A) and serum placental growth factor (PlGF) were collected without performing a risk assessment for pre-eclampsia. Information on acetylsalicylic acid use was recorded. After delivery, pregnancy outcome, including gestational age at delivery and pre-eclampsia diagnosis, was recorded. Pre-eclampsia risk assessment for each woman was calculated blinded to outcome using the FMF screening algorithm following adjustment to the Danish population. Detection rates (DRs) of the FMF algorithm were calculated for a fixed screen-positive rate (SPR) of 10% and for the SPR achieved in the current Danish screening. RESULTS: A total of 8783 pregnant women were included, with a median age of 30.8 (interquartile range (IQR), 28.1-33.9) years. The majority were white (95%), naturally conceiving (90%), non-smokers (97%) and had no family history of pre-eclampsia (96%). The median body mass index was 23.4 (IQR, 21.2-26.6) kg/m2 . A complete risk assessment including maternal characteristics, MAP, UtA-PI, PlGF and PAPP-A was available for 8156 women (92.9%). In these women, UtA-PI was measured bilaterally with a median value of 1.58 (IQR, 1.27-1.94) and the median resting MAP of 80.5 (IQR, 76.1-85.4) mmHg in two consecutive measurements. Among these, 303 (3.7%) developed pre-eclampsia, including 55 (0.7%) cases of pre-eclampsia with delivery < 37 weeks of gestation and 16 (0.2%) cases of pre-eclampsia with delivery < 34 weeks. At a SPR of 10%, combined screening using the FMF algorithm based on maternal characteristics, MAP, UtA-PI, PlGF and PAPP-A had a DR of 77.4% (95% CI, 57.6-97.2%) for pre-eclampsia with delivery < 34 weeks, 66.8% (95% CI, 54.4-79.1%) for pre-eclampsia with delivery < 37 weeks and 44.1% (95% CI, 38.5-49.7%) for pre-eclampsia with delivery at any gestational age. The current Danish screening strategy using maternal risk factors detected 25.0% of women with pre-eclampsia with delivery < 34 weeks and 19.6% of women with pre-eclampsia with delivery < 37 weeks at a SPR of 3.4%. When applying the FMF algorithm including maternal characteristics, MAP, UtA-PI and PlGF at the fixed SPR of 3.4%, the DRs were 60.5% (95% CI, 36.9-84.1%) for PE with delivery < 34 weeks and 45.2% (95% CI, 32.0-58.5%) for PE with delivery < 37 weeks. CONCLUSION: In this large Danish multicenter study, the FMF algorithm based on maternal characteristics, MAP, UtA-PI, PlGF and PAPP-A predicted 77.4% of cases with pre-eclampsia with delivery < 34 weeks and 66.8% of cases with pre-eclampsia with delivery < 37 weeks of gestation at a SPR of 10%, suggesting that the performance of the algorithm in a Danish cohort matches that in other populations. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Riishede I, Rode L, Sperling L, et al. Pre-eclampsia screening in Denmark (PRESIDE): national validation study. Ultrasound Obstet Gynecol. 2023. PMID: 36840981. doi:10.1002/uog.26183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。